{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"1.930","rs_stock_flag":false,"fiscal_year_end":"31 Dec 2024","hist_closedate":"25 Sep 2025","replication_method":null,"amt_os":"720,160,912","primaryexch":"HKEX","ric":"2137.HK","product_subtype":null,"db_updatetime":"26 Sep 2025 18:38","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.0,"inline_upper_strike_price":"","sedol":"BND89B5","am":"9.83","iv":"","ew_strike":"","as":"1.880","geographic_focus":null,"incorpin":"Cayman Islands","etp_baseCur":null,"ew_amt_os":"","bd":"1.870","registrar":"Tricor Investor Services Ltd.","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"500","update_time":"2025-09-26 10:38:37.0","lo52":"0.800","shares_issued_date":"22 Sep 2025","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"Zhi Hong","underlying_ric":"2137.HK","hi52":"3.090","issuer_name":"Brii Biosciences Ltd. - B","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"26 Sep 2025 16:08","aum_date":"","lo":"1.860","mkt_cap":"1.34","f_aum_hkd":null,"ew_sub_per_to":"","ls":"1.870","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"Healthcare - Pharmaceuticals & Biotechnology","ew_desc":null,"inception_date":"","nc":"-0.060","aum":"","issued_shares_class_B":null,"vo":"5.25","secondary_listing_flag":false,"listing_date":"13 Jul 2021","issued_shares_class_A":null,"as_at_label":"as at","ew_amt_os_dat":"","nm":"Brii Biosciences Ltd. - B","nm_s":"BRII - B","sym":"2137","inline_lower_strike_price":"","listing_category":"Primary Listing","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.010","strike_price":"","summary":"Brii Biosciences Ltd is a biotechnology company principally focused on developing therapies for infectious diseases and central nervous system diseases. The Company's HBV portfolio products include the proprietary therapeutic vaccine BRII-179, the siRNA BRII-835 (elebsiran), and the neutralizing antibody BRII-877 (tobevibart). The Company owns a broad pipeline of multiple innovative drug candidates that focus on infectious diseases and central nervous system diseases. The Companyâ€™s products are applied in infectious diseases, such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), multi-drug resistant (MDR) or drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases. The Company mainly conducts its businesses in China market.","op":"1.930","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"Biotechnology","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"Room 1920, 19/F<br/>Lee Garden One<br/>33 Hysan Avenue<br/>Causeway Bay, Hong Kong","pc":"-3.11","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":"RMB","hdr":false,"launch_date":"","hc":"1.930","isin":"KYG1645A1094","moneyness":""}},"qid":"1758890393611"}
